ReadyMedical

EFFICACY TESTS

Image

ANTI-AGING: HA+GF

Human fibroblasts have been treated in vitro with ReadyMedical special compound of sonicated Hyaluronic Acid + Growth Factors with the wound healing technique. After 24 hours the treated cells had increased their motility and proliferation of up to 44%, compared to the untreated cells used as negative controls (1).

Using the inserts, a gap of 500 μm was created in a confluent cell colture monolayer and the wound closure was evaluated by measuring the width of injury line, taking pictures at regular interval of 24 hours.

The effect of the Product ReadyMedical HA + GF was evaluated as the capability of cells to reduce the original gap of 500 μm (100% of wound closure), comparing the pictures, taken at different times with the corresponding pictures of the initial wounded monolayer. The result has been the complete wound closure of the cells treated with ReadyMedical HA + GF after 72 hours.

1) UB-CARE – UNIVERSITY OF PAVIA. Report nr. PRL/17/LC1/P2. Date: 25/07/2017. The full version of this study is available upon request.

POST-TREATMENT: REPAIRING HA+PFD+PA

The study has been conducted through the in vitro evaluation of the anti-inflammatory activity of ReadyMedical HA+PFD+PA (1) on human fibroblasts.
A human keratinocyte cell line has been treated with this special compound of sonicated Hyaluronic Acid + Perfluorodecalin + Physalis Angulata. The treated cells showed a decrease of ~ 94% of inflammation compared to the untreated cells used as negative control.
The anti-inflammatory activity has been calculated measuring the IL-8 levels 24 hours after treating the fibroblasts with the product; the result was a decrease of the IL-8 levels between 93,25% and 94,82%, compared to the untreated cells.
IL-8 is the most direct and reliable marker of inflammation among the wide cytokine family. Cytokines are small proteins known to play an important role in the immune system; in particular they are able to influence the activation, maturation, growth and differentiation of several cell populations. IL-8 secretion is particularly active in chronic inflammation conditions, thus measurement of this cytokine in an in vitro model, composed by fibroblasts, represents a useful and sensitive tool to assess the anti-inflammatory effect of a topical product.

1) UB-CARE – UNIVERSITY OF PAVIA. Report nr. AIF/17/LC1/P1. Date: 12/07/2017. The full version of this study is available upon request.

Image

ACNE: HA + AC

STUDY 1
In vitro EVALUATION OF THE PROPIONIBACTERIUM ACNES GROWTH INHIBITION AFTER THE TREATMENT
WITH READYMEDICAL ACNE HA + AC
The inhibitory activity of the ReadyMedical Acne product was evaluated by treating the Propionibacterium acnes bacterial strain with the tested product. At two time intervals (6h and 24h), 100 μl of the mixture were plated on selective agar plates in order to verify the possible inhibition of the bacterial growth of Propionibacterium acnes, represented in Figure.
Image
The results obtained show that the ReadyMedical Acne product determines a decrease equal to 99.9% of the growth of the Propionibacterium acnes strain after 6 hours and after 24 hours of contact, which was highly significant under the conditions tested.

Figure: Growth inhibition of P. acnes in absence (Inoculum ctrl) and presence (100%) of the ReadyMedical Acne product after different times of contact.
STUDY 2
In vitro EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF READY MEDICAL ACNE HA + AC AFTER PROPIONIBACTERIUM ACNES STIMULUS ON HUMAN KERATINOCYTES
The anti-inflammatory activity of the product ReadyMedical Acne after stimulation with P.acnes was evaluated in HaCat cells, measuring the expression of IL-8 by an ELISA kit (2). The concentrations to be used for the anti-inflammatory assay are 56.2 and 46.4 mg/ml, based on the cell viability assay. Positive control is represented by untreated cells and stimulated with P.acnes colture.
Image
The obtained results demonstrate a decrease in IL-8 levels, following a pro-inflammatory stimulus, in human keratinocytes treated for 8 h. Samples treated with the product ReadyMedical Acne show a decrease in IL-8 levels of 39.39% and 41.69% (following treatment with 56.42 and 46.4 mg/ml, respectively) compared to the stimulated control (Ctrl + P.acnes), resulted to be highly significant for both tested concentrations.

Figure: Shows the effect of 8 h treatment with the test- ed product on IL-8 production, after P. acnes stimulation.
Image

ReadyMedical is a JointVenture between :

Image
Image
Image